181 related articles for article (PubMed ID: 12168882)
1. Distribution of p53 codon 72 polymorphisms in ovarian tumour patients and their prognostic significance in ovarian cancer patients.
Høgdall EV; Høgdall CK; Christensen L; Glud E; Blaakaer J; Bock JE; Vuust J; Nørgaard-Pedersen B; Kjaer SK
Anticancer Res; 2002; 22(3):1859-64. PubMed ID: 12168882
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of a polymorphism in intron 2 of the p53 gene in ovarian cancer patients. From the Danish "Malova" Ovarian Cancer Study.
Høgdall EV; Kjaer SK; Glud E; Christensen L; Blaakaer J; Vuust J; Bock JE; Norgaard-Pedersen B; Hogdall CK
Anticancer Res; 2003; 23(4):3397-404. PubMed ID: 12926080
[TBL] [Abstract][Full Text] [Related]
3. p53 gene mutations and codon 72 polymorphism in ovarian carcinoma patients from Serbia.
Malisic E; Jankovic R; Slavkovic D; Milovic-Kovacevic M; Radulovic S
J BUON; 2010; 15(1):101-6. PubMed ID: 20414935
[TBL] [Abstract][Full Text] [Related]
4. P53 mutations in tissue from Danish ovarian cancer patients: from the Danish "MALOVA" ovarian cancer study.
Høgdall EV; Kjaer SK; Blaakaer J; Christensen L; Glud E; Vuust J; Høgdall CK
Gynecol Oncol; 2006 Jan; 100(1):76-82. PubMed ID: 16183105
[TBL] [Abstract][Full Text] [Related]
5. Germline polymorphism of p53 codon 72 in gynecological cancer.
Ueda M; Terai Y; Kanda K; Kanemura M; Takehara M; Yamaguchi H; Nishiyama K; Yasuda M; Ueki M
Gynecol Oncol; 2006 Jan; 100(1):173-8. PubMed ID: 16168468
[TBL] [Abstract][Full Text] [Related]
6. Potential increase in the prognostic value of p53 mutation by Pro72 allele in stage I non-small-cell lung cancer.
Chien WP; Wong RH; Wu TC; Cheng YW; Chen CY; Lee H
Ann Surg Oncol; 2009 Jul; 16(7):1918-24. PubMed ID: 19434453
[TBL] [Abstract][Full Text] [Related]
7. P53 gene status in patients with advanced serous epithelial ovarian cancer in relation to response to paclitaxel- plus platinum-based chemotherapy and long-term clinical outcome.
Gadducci A; Di Cristofano C; Zavaglia M; Giusti L; Menicagli M; Cosio S; Naccarato AG; Genazzani AR; Bevilacqua G; Cavazzana AO
Anticancer Res; 2006; 26(1B):687-93. PubMed ID: 16739339
[TBL] [Abstract][Full Text] [Related]
8. The p53 codon 72 polymorphism and lung cancer risk.
Fan R; Wu MT; Miller D; Wain JC; Kelsey KT; Wiencke JK; Christiani DC
Cancer Epidemiol Biomarkers Prev; 2000 Oct; 9(10):1037-42. PubMed ID: 11045785
[TBL] [Abstract][Full Text] [Related]
9. p53 and p21 genetic polymorphisms and susceptibility to endometrial cancer.
Roh JW; Kim JW; Park NH; Song YS; Park IA; Park SY; Kang SB; Lee HP
Gynecol Oncol; 2004 May; 93(2):499-505. PubMed ID: 15099969
[TBL] [Abstract][Full Text] [Related]
10. p53 Codon 72 polymorphism predicts the pathologic response to neoadjuvant chemotherapy in patients with breast cancer.
Xu Y; Yao L; Ouyang T; Li J; Wang T; Fan Z; Lin B; Lu Y; Xie Y
Clin Cancer Res; 2005 Oct; 11(20):7328-33. PubMed ID: 16243804
[TBL] [Abstract][Full Text] [Related]
11. Determination of p53 genotypes in oral cancer patients from India.
Tandle AT; Sanghvi V; Saranath D
Br J Cancer; 2001 Mar; 84(6):739-42. PubMed ID: 11259085
[TBL] [Abstract][Full Text] [Related]
12. Proline homozygosity in codon 72 of p53 is a factor of susceptibility for thyroid cancer.
Granja F; Morari J; Morari EC; Correa LA; Assumpção LV; Ward LS
Cancer Lett; 2004 Jul; 210(2):151-7. PubMed ID: 15183530
[TBL] [Abstract][Full Text] [Related]
13. [Correlation analysis between clinical phenotypes of keloids and polymorphism of p53 gene codon 72].
Liu Y; Gao J; Liu X; Lu F; Liu H
Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi; 2008 Dec; 22(12):1433-6. PubMed ID: 19137883
[TBL] [Abstract][Full Text] [Related]
14. An investigation of relationships between hypoxia-inducible factor-1 alpha gene polymorphisms and ovarian, cervical and endometrial cancers.
Konac E; Onen HI; Metindir J; Alp E; Biri AA; Ekmekci A
Cancer Detect Prev; 2007; 31(2):102-9. PubMed ID: 17418979
[TBL] [Abstract][Full Text] [Related]
15. Polymorphisms in p53, GSTP1 and XRCC1 predict relapse and survival of gastric cancer patients treated with oxaliplatin-based adjuvant chemotherapy.
Huang ZH; Hua D; Du X
Cancer Chemother Pharmacol; 2009 Oct; 64(5):1001-7. PubMed ID: 19247656
[TBL] [Abstract][Full Text] [Related]
16. No relationship observed between human p53 codon-72 genotype and HPV-associated cervical cancer in a population group with a low arginine-72 allele frequency.
Govan VA; Loubser S; Saleh D; Hoffman M; Williamson AL
Int J Immunogenet; 2007 Jun; 34(3):213-7. PubMed ID: 17504512
[TBL] [Abstract][Full Text] [Related]
17. Evidence for an association of TP53 codon 72 polymorphism with breast cancer risk.
Damin AP; Frazzon AP; Damin DC; Roehe A; Hermes V; Zettler C; Alexandre CO
Cancer Detect Prev; 2006; 30(6):523-9. PubMed ID: 17113725
[TBL] [Abstract][Full Text] [Related]
18. Homozygous proline at codon 72 of p53 as a potential risk factor favoring the development of undifferentiated thyroid carcinoma.
Boltze C; Roessner A; Landt O; Szibor R; Peters B; Schneider-Stock R
Int J Oncol; 2002 Nov; 21(5):1151-4. PubMed ID: 12370767
[TBL] [Abstract][Full Text] [Related]
19. P53 mutation does not affect prognosis in ovarian epithelial malignancies.
Fallows S; Price J; Atkinson RJ; Johnston PG; Hickey I; Russell SE
J Pathol; 2001 May; 194(1):68-75. PubMed ID: 11329143
[TBL] [Abstract][Full Text] [Related]
20. Arginine and proline alleles of the p53 gene are associated with different locations of gastric cancer.
Lai KC; Chen WC; Tsai FJ; Li SY; Jeng LB
Hepatogastroenterology; 2005; 52(63):944-8. PubMed ID: 15966238
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
